Hydrogen sulfide and/or nitrite in the treatment and prevention of atrial fibrillation
US11116731B2 · kind B2 · utility
0Cited by
2References
10Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2018 |
| Grant date | Sep 14, 2021 |
| Priority date | — |
| Expiry date | Feb 20, 2038 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC01B17/16
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
A method of treating Atrial Fibrillation or a pre-Atrial Fibrillation condition in a mammal, preferably a human, comprising administering a therapeutically effective amount of one of organic or inorganic sulfide, organic or inorganic nitrite, both organic or inorganic sulfide and organic or inorganic nitrite, or pharmacologically acceptable salts, solvates, esters, amides, clathrates, stereoisomers, enantiomers, prodrugs or analogs thereof, or a combination thereof.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.